Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 1997

View Archived Issues

Zambon develops dual ACE/NEP inhibitors

Leukotriene antagonists prepared by Leo

Agents for increasing HDL cholesterol from American Home Products

MS&D continues to pursue antimigraine agents

BDNF shows potential for stroke therapy in rat model

Novel antibacterial oxazolidinones from Pharmacia & Upjohn

New treatment options for ALS

Yamanouchi discloses Na+/H+-exchange inhibitors for cardiovascular indications

Eisai discloses acridone antiallergy agents

Sankyo discovers gelatinase inhibitors

5-HT4 agonists from Yoshitomi with broad therapeutic potential

Nippon Shinyaku reveals new series of carboxylic acid derivatives

Orally active ET antagonist from BMS in clinical trials

Japanese approval for Taxol

Selective 15-LO inhibitor effective in animal model of atherosclerosis

Company profile: UroCor

ID Biomedical: FY 1997 highlights

Taiho's R&D pipeline

Bristol-Myers Squibb licenses cancer vaccines from Progenics

The Liposome Company reacquires TLC-D-99 rights from Pfizer, reports phase III results

HGS achieves milestone in and expands agreement with Roche

Multicenter European clinical trials of REPEL initiated

Onyx reports on clinical progress of ONYX-015

FDA clears new indication and new labeling for Zoloft

EchoGen enters clinical trials in Japan

MedImmune granted license to humanized antibody patents

Epix Medical receives milestone payment

CTL ImmunoTherapies: newly formed company for the development of anticancer vaccines

Boston Life Sciences begins preclinical program for ophthalmic indications of antiangiogenic product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...